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NMDA Antagonist Peptide Supplementation Enhances Pain Alleviation
by Adrenal Medullary Transplants
Farinaz NasiriNezhad1 and Jacqueline Sagen
The Miami Project to Cure Paralysis, University of Miami School of Medicine, Miami, FL
Spinal transplantation of adrenal medullary chromaffin cells has been shown to decrease pain responses in
several animal models. Improved potency may be possible by engineering cells to produce greater levels of
naturally derived analgesics. As an initial screen for potential candidates, adrenal medullary transplants were
evaluated in combination with exogenously administered neuropeptides in rodent pain models. Histogranin
is a 15-amino acid peptide that exhibits NMDA receptor antagonist activity. The stable derivative [Ser1]histo-
granin (SHG) can attenuate pain symptoms in some animal models. The formalin model for neurogenic
inflammatory pain and the chronic constriction injury (CCI) model for neuropathic pain were used to evalu-
ate the combined effects of chromaffin cell transplantation and intrathecal (IT) SHG injections. Animals
were implanted with either adrenal medullary or control striated muscle tissue in the spinal subarachnoid
space. For evaluation of formalin responses, animals were pretreated with SHG (0.5, 1.0, 3.0 µg) followed
by an intraplantar injection of formalin, and flinching responses were quantified. Pretreatment with SHG
had no significant effect on flinching behavior in control animals at lower doses, with incomplete attenuation
only at the highest dose. In contrast, 0.5 µg SHG significantly reduced flinching responses in animals with
adrenal medullary transplants, and 1.0 µg nearly completely eliminated flinching in these animals in the
tonic phase. For evaluation of effects on neuropathic pain, animals received transplants 1 week following
CCI, and were tested for thermal and mechanical hyperalgesia and cold allodynia before and following SHG
treatment. The addition of low doses of SHG nearly completely eliminated neuropathic pain symptoms in
adrenal medullary transplanted animals, while in control transplanted animals only thermal hyperalgesia was
attenuated, at the highest dose of SHG. These results suggest that SHG can augment adrenal medullary
transplants, and the combination may result in improved effectiveness and range in the treatment of chronic
pain syndromes.
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INTRODUCTION neuropathic pain models (5,6,10,11), central pain mod-
els (2,7,44,45), and wind-up (14). However, analgesic
effects of chromaffin cell transplants are not always ob-The transplantation of cells into the CNS can have
therapeutic benefit by providing a sustained and renew- served, as described in recent reports using acute pain
models and the formalin test (18,19). Variations in trans-able local source of naturally derived pharmacologically
active agents. The use of this approach in the manage- plantation or testing procedures between laboratories
may account for some of these differences. A recentlyment of pain has been explored in several laboratories.
Most of this work has focused on the transplantation of completed open label clinical trial utilizing adrenal med-
ullary allografts in terminal cancer patients suggestedadrenal medullary chromaffin cells in the spinal suba-
rachnoid space, as these cells produce numerous agents that opioid requirements for pain control could be de-
creased or stabilized in a majority of patients in contrastwith analgesic or antinociceptive activity, including opi-
oid peptides, catecholamines, and endogenous NMDA to the usual dose escalation observed during disease pro-
gression (15). However, a controlled clinical trial usingantagonists (17,29,39,41). Adrenal medullary tissue or
isolated chromaffin cell transplants have shown efficacy encapsulated bovine chromaffin cells for terminal cancer
pain reportedly did not reach significant clinical efficacyin various preclinical pain models including the formalin
test (3,24,33,35,36,38,42), chronic inflammation (30,40), (Astra AB, Sweden; unpublished findings), possibly due
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to the relatively low numbers of cells (hence achieving pathic pain using the chronic constriction injury (CCI)
model (1). For evaluation of effects of SHG supplemen-subtherapeutic doses of released analgesic agents) that
can be accommodated by the capsules. tation with adrenal medullary transplants in inflamma-
tory pain, animals with intrathecal catheters and eitherThus, it is likely that adrenal medullary chromaffin
cells, while possessing a promising analgesic therapeutic adrenal medullary or control striated muscle transplants
in the subarachnoid space (see below for surgical proce-cocktail and the cellular machinery for sustainable local
delivery of these agents, may produce levels too low for dures) received intrathecal injections of SHG (0.5, 1.0,
or 3.0 µg) 15 min prior to intraplantar formalin injectionmanagement of severe chronic pain, particularly in the
clinical setting given the practical limitations of cell and observation of pain-related behaviors (see below for
behavioral testing procedures). For effects on neuro-transplantation. The goal of ongoing studies in our labo-
ratory is to increase the analgesic efficacy of trans- pathic pain, a battery of tests for allodynia and hyperal-
gesia (see below) was given prior to CCI induction, 1planted cells by supplementation with additional or in-
creased levels of therapeutic agents. For this purpose, week following CCI surgery, and every other day begin-
ning 1 week following transplantation through studynaturally derived neuropeptides have been selected, as
these may be ultimately genetically engineered to pro- completion. At each test point following transplantation,
baseline responses and responses 15 min following intra-duce high potency analgesic chromaffin cells for trans-
plantation. As an initial screen for potential peptide can- thecal injection of SHG or saline were determined. Doses
of SHG (0.5, 1.0, or 3.0 µg) or saline vehicle were in-didates, adrenal medullary transplants are evaluated in
combination with exogenously administered neuropep- jected intrathecally in 10 µl volumes followed by 10 µl
saline flush. Doses were rotated such that each animaltides in rodent pain models. A promising candidate is
the 15-amino acid peptide, histogranin, as it possesses received all doses during the course of the study. There
were 9–14 animals in all transplant/pharmacologic treat-NMDA antagonist-like activity (17,31), a class of agents
that have been shown to reduce hyperalgesia and allo- ment groups. SHG was custom synthesized by Research
& Diagnostic Antibodies (Berkeley, CA).dynia, attenuate opioid tolerance, and enhance opioid
analgesia (20,21,25–28). In addition, chromaffin cells
Surgical Procedurespossess the cellular machinery to process histogranin, as
the natural form is produced in the adrenal medulla (16). To induce unilateral peripheral neuropathic pain, the
common sciatic nerve of anesthetized animals was ex-The stable analog, [Ser1]histogranin (SHG) was selected,
as it has the potential to produce more sustained NMDA posed on one side at the midthigh level and four 4-0
chromic gut ligatures spaced about 1 mm apart werereceptor antagonism for chronic pain therapy, and should
be synthesizable by engineered mammalian cells. Previ- loosely tied around the sciatic nerve proximal to the tri-
furcation, constricting the nerve to a barely discernableous findings in our laboratory have shown that intrathe-
cally injected SHG can attenuate, although not completely degree, such that circulation through the epineural vas-
culature was not interrupted. Following surgery, theblock, neuropathic, inflammatory, and NMDA-mediated
hyperalgesia (9,12,32,35). The goal of the present stud- musculature was sutured in layers, and the skin closed
with wound clips.ies was to determine whether SHG would be a promis-
ing candidate for producing enhanced potency chromaf- All animals were implanted with an intrathecal cathe-
ter prior to initiation of behavioral testing to administerfin cells by screening this agent in combination with
adrenal medullary transplants for attenuation of neuro- doses of SHG directly into the CSF. For animals with
CCI, catheter placement was done 1 week following in-genic inflammatory and neuropathic pain. Preliminary
results were presented at the American Society for Neu- duction of neuropathic pain. Intrathecal (IT) catheters
(8.0 cm of PE-10 tubing) were introduced via a slit inral Transplantation and Repair meeting (22,23).
the atlanto-occipital membrane and carefully threaded
MATERIALS AND METHODS caudally in the intrathecal space, such that the tips ended
Animals at the level of the thoraco-lumbar spinal cord.
At the time of catheter implantation, animals wereMale Sprague-Dawley rats (Charles River) weighing
also transplanted with either adrenal medullary or con-200–250 g at the initiation of the studies were used. All
trol striated muscle tissue in the spinal subarachnoid space.animal procedures followed NIH guidelines and were
Both adrenal medullary tissue and striated muscle tissueapproved by the University of Miami Animal Care and
were obtained from adult male Sprague-Dawley donors.Use Committee.
Adrenal medullary tissue was dissected from two adre-
Experimental Design nal glands in ice-cold HBSS and cut into small pieces
(<0.5 mm3) as described in previous studies (3,11,30,33).Animals were assessed for either neurogenic inflam-
matory pain using the formalin test or peripheral neuro- Transplant control animal received equal volume of stri-
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ated muscle tissue from donor animals. For implanta- (normal intact rats usually do not respond to this stimu-
lus; hence receive a score of 0): No. of trials accompa-tion, a laminectomy was performed to expose lumbar
segments L1–L2 and tissue was implanted in the suba- nied by foot withdrawals/No. of total trials × 100.
rachnoid space via a slit in the dura and arachnoid mem-
Data Evaluationbrane under the aid of a dissecting microscope. Follow-
All behavioral studies were done by an observer blindeding transplantation procedures the back musculature was
to the experimental treatment. Data are expressed assutured with 3-0 silk and the skin closed with wound
means ± SEM. Statistical comparisons between trans-clips. After all surgical procedures, animals were re-
plant/pharmacologic treatment groups were done usingturned to their cages and food and water were available
two-way ANOVA (repeated measures) and the New-ad libitum.
man-Keuls test for multiple post hoc comparisons (37).
Behavioral Evaluation For confirmation of adrenal graft viability, a sampling of
transplanted animals were perfused intracardially, theirAnimals were evaluated for formalin pain responses
spinal cords dissected, and graft tissue stained for tyro-1 week following adrenal medullary transplantation and
sine hydroxylase immunocytochemistry (DiaSorin, di-intrathecal catheter placement. To accomplish this, 50
luted 1:1000).µl of 5% formalin was injected in the plantar surface of
one hind paw. The number of flinches and licking be- RESULTShaviors that occurred during the first minute of each
Effects of SHG Supplementation on Antinociceptive5-min interval up to 1 h was counted as described in
Effects Transplants in Inflammatory Painprevious studies (3,33,35,42). For evaluation of pain re-
sponses using the CCI model, a battery of sensory tests Figure 1 shows the effects of pretreatment with 0.5
µg (top panel), 1.0 µg (middle panel) or 3.0 µg (lowerwas performed in sequence. Responses to noxious heat
(thermal hyperalgesia test) were evaluated using a paw panel) SHG on the formalin responses in animals with
adrenal medullary or control transplants. Typical bipha-withdrawal test (13). Responses to noxious mechanical
pressure (mechanical hyperalgesia) was assessed using sic formalin flinching responses were observed in most
cases: phase 1, thought to be indicative of acute pain,a pressure withdrawal test (Randall-Selitto apparatus),
and responses to innocuous cold (cold allodynia) were occurred during the first minute postformalin, and phase
2, thought to be indicative of tonic, more prolongeddetermined using the acetone test. To assess response to
a noxious thermal stimulus, rats are placed beneath an pain, occurred approximately between 20 and 50 min
postformalin, separated by a quiescent interphase be-inverted clear plastic cage on an elevated glass floor and
allowed to acclimate for 5 min. A radiant heat source tween phase 1 and phase 2. Following treatment with
the lowest dose of SHG, animals with adrenal medullarybeneath the glass was aimed at the plantar hind paw and
activated a timer. Withdrawal latencies were the length transplants showed significantly reduced flinching com-
pared with animals with control striated muscle transplantsof time between the activation of the heat source and the
hind paw withdrawal from the glass (normal baseline [overall F(1, 12) = 22.64, p < 0.001]. The attenuated flinch-
ing in adrenal transplanted animals was observed only10 s). To avoid tissue damage in the absence of a
withdrawal, the cutoff was set at 20 s. Three trials were in phase 2 at this dose, notably at 30–40 min after for-
malin (p < 0.05); no significant differences were notedgiven at least 30 s apart, the average values used for
statistical analysis. To assess sensitivity to a noxious for phase 1 responses (p > 0.05). In contrast, 1.0 µg
SHG injected intrathecally produced significantly re-mechanical stimulus, the rats were wrapped in a towel
and an increasing force (48 g/s) was applied to the plan- duced flinching in both phases of the formalin response
in animals with adrenal medullary compared with con-tar surface of the hind paw until the rat reacted with a
withdrawal response (normal baseline 10 in arbitrary trol transplants [overall F(1, 12) = 54.61, p < 0.001; p <
0.05 for phase 1 and 2]. Phase 1 responses were lower inscale units). The apparatus automatically terminated at
1000 g (25 in scale units) in the absence of a response. adrenal medullary transplanted than control transplanted
animals following 1.0 µg SHG pretreatment, but theseTo evaluate cold allodynia, the animals were placed be-
neath an inverted plastic cage on an elevated mesh floor responses were only partially attenuated and not com-
pletely eliminated. In contrast, phase 2 flinching wasand a drop of acetone was applied to the plantar surface
of the foot using polyethylene tubing connected to a sy- markedly attenuated and nearly completely eliminated
for the duration of the response period (20–50 min) inringe. The acetone bubble was gently touched to the heel
and quickly spread over the proximal half of the plantar these animals. This dose of SHG was more potent in
reducing formalin responses than the lower dose in adre-surface of the foot. Acetone was applied five times with
at least 3-min intervals between applications. The fre- nal medullary grafted animals (p < 0.05). In contrast, 1.0
µg SHG did not reduce responses compared with 0.5 µgquency of foot withdrawal was expressed as a percent
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flinching in previous reports (4,8,34,43). At this highest
SHG dose studied, formalin flinching was reduced to an
equivalent extent in both adrenal medullary and control
transplanted animals (p > 0.05).
Effects of SHG Supplementation on Antinociceptive
Effects Transplants in Neuropathic Pain
Figures 2–4 show the effects of SHG pretreatment
on neuropathic pain responses in animals with adrenal
medullary (top panels) and striated muscle control
(lower panels) transplants. Responses to noxious heat
are shown in Figure 2. At 1 week following CCI, animals
showed reduced hind paw withdrawal latencies (thermal
hyperalgesia) compared with presurgical baseline re-
sponses in all animals (p < 0.05). Following adrenal
medullary transplantation, thermal hyperalgesia was at-
tenuated, although not completely reversed (predrug
treatment solid bars in Fig. 2 top panel; p < 0.05 com-
pared with both CCI and baseline responses). In con-
trast, thermal hyperalgesia was not altered by control
striated muscle transplants (predrug treatment solid bars
in Fig. 2 bottom panel; p > 0.05 compared with CCI; p <
0.05 compared with baseline responses). The combined
effects of adrenal medullary transplants supplemented
with SHG markedly reduced, and nearly eliminated, the
thermal hyperalgesia produced by the peripheral nerve
constriction injury compared with effects in the control
transplant group [overall F(1, 22) = 10.06, p < 0.001].
Following the intrathecal pretreatment with SHG, ther-
mal hyperalgesia was reduced and thermal withdrawal
responses nearly restored to pre-CCI baseline levels in
animals with adrenal medullary transplants (p > 0.05
compared with both baseline and saline pretreatment).
All SHG doses tested produced this result and further
reduced hyperalgesia compared with the effects of the
Figure 1. Effects of [Ser1]histogranin (SHG) supplementation adrenal medullary transplants alone (p < 0.05). SHG
and adrenal medullary or striated muscle transplants in the spi- also attenuated thermal hyperalgesia in control trans-
nal subarachnoid space on formalin-evoked flinching responses. planted animals, but only at the highest dose tested (P <SHG was given intrathecally at 0.5 µg (top panel), 1.0 µg
0.05 compared with CCI at 3.0 µg SHG). Lower doses(middle panel), or 3.0 µg 15 min prior to intraplantar injection
of formalin (5%). Each point represents the mean ± SEM num- of SHG did not alter responses to noxious thermal stim-
ber of hind paw flinches observed during the first minute of uli in control transplanted animals (p > 0.05).
each 5-min interval following the formalin in animals with ad- CCI also produced mechanical hyperalgesia observed
renal medullary (triangles) or control (circles) transplants. n = by 1 week following (Fig. 3; p < 0.05 compared with11–15 animals per transplant group.
baseline). As observed in previous studies, effects of ad-
renal medullary transplants on noxious mechanical re-
sponses were markedly weaker than those on noxiousSHG in animals with control transplants (p > 0.05). The
highest SHG dose tested also produced lowered flinch- thermal responses (Fig. 3, top panel). However, supple-
mentation with SHG significantly attenuated mechanicaling in animals with adrenal medullary transplants, but
this was not significantly different from the lower doses hyperalgesia in these animals (p < 0.05 compared with
both post-CCI and saline pretreatment responses), nearlyof SHG (p > 0.05). However, in contrast to the lower
SHG doses, 3.0 µg SHG produced moderate attenuation reversing responses to noxious mechanical stimuli to
pre-CCI levels in these animals (p > 0.05 compared withof flinching responses in control transplanted animals
(p < 0.05). Similarly, SHG in this dose range and other baseline). SHG pretreatment in muscle transplanted ani-
mals showed a trend towards attenuating mechanical hy-NMDA antagonists have been found to reduce phase 2
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medullary (top panel) and control striated muscle (bot-
tom panel) transplants. Prior to CCI, lifting withdrawal
responses to hind paw plantar acetone application were
nearly zero (baseline). Following CCI, cold allodynia
was apparent as approximately 50–60% hind paw lifting
in response to acetone. Adrenal medullary transplants
showed a nonsignificant tendency toward reduced allo-
dynia. However, following intrathecal pretreatment with
SHG, cold allodynia was markedly attenuated in animals
with adrenal medullary transplants (p < 0.05 compared
with both post-CCI and saline pretreatment). In contrast,
Figure 2. Effect of [Ser1]histogranin supplementation and ad-
renal medullary or striated muscle transplants in the spinal
subarachnoid space on complete chronic constriction injury
(CCI)-induced thermal hyperalgesia. Baseline latencies (BL,
open bars) of rats were evaluated prior to unilateral CCI, after
CCI (cross-hatched bars), and before (Pre-SHG; solid bars)
and after (Post-SHG, diagonal bars) intrathecal treatment with
saline vehicle or SHG (0.5, 1.0, or 3.0 µg). Mean latencies ±
SEM in adrenal medullary (top panel, n = 14) or striated mus-
cle (bottom panel, n = 10) transplanted animals are shown.
peralgesia in muscle transplanted animals, particularly
at 3.0 µg, but this did not reach statistical significance
(p > 0.05 compared with post-CCI and with saline pre- Figure 3. Effect of [Ser1]histogranin supplementation and ad-
treatment). As observed for thermal hyperalgesia, the renal medullary or striated muscle transplants in the spinal
combined effects of adrenal medullary grafts with SHG subarachnoid space on complete chronic constriction injury
(CCI)-induced mechanical hyperalgesia. Baseline latencies (BL,supplementation nearly eliminated the mechanical hy-
open bars) of rats were evaluated prior to unilateral CCI, afterperalgesia generated by peripheral nerve injury in these
CCI (cross-hatched bars), and before (Pre-SHG; solid bars)animals, in contrast to striated muscle transplants [over-
and after (Post-SHG, diagonal bars) intrathecal treatment with
all F(1, 22) = 9.31, p < 0.001]. saline vehicle or SHG (0.5, 1.0, or 3.0 µg). Mean thresholds ±
Figure 4 shows responses to innocuous cold (acetone SEM in adrenal medullary (top panel, n = 14) or striated mus-
cle (bottom panel, n = 10) transplanted animals are shown.application) in response to SHG pretreatment in adrenal
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tion. The morphology of this example is similar to that
observed in previous studies in our laboratory (11,29,33,
35,40).
DISCUSSION
The aim of these studies was to evaluate whether sup-
plementation with a naturally derived analgesic agent
could be useful in enhancing the antinociceptive effects
of adrenal medullary transplants. This approach is an
initial screen for the long-term goal of engineering novel
and more potent cell lines producing additional or higher
levels of analgesic agents for chronic pain management.
Results of the studies indicate that supplementation with
SHG, a stable analog of NMDA antagonist peptide his-
togranin, can augment reduction of neuropathic and in-
flammatory pain in animals with adrenal medullary trans-
plants in the spinal subarachnoid space.
A histogranin analog was selected, because this natu-
rally occurring peptide has been shown to possess
NMDA antagonist activity, a potentially useful pharma-
cologic supplement in chronic pain treatment, as NMDA
antagonists can augment opioid analagesia, reduce toler-
ance development to opioids, and reduce the abnormal
hyperalgesic components of neuropathic and inflamma-
tory pain without altering normal pain sensitivity (20,
21,25–28). Previous findings in our laboratory have
demonstrated that SHG can attenuate some symptoms of
both neuropathic and inflammatory pain (9,32,34). An
additional advantage of this peptide family is that histo-
granin is produced naturally in chromaffin cells; thus,
the cellular machinery for proper processing and secre-
tion should be available if SHG is selected for genera-
tion of more potent chromaffin cell lines.
Figure 4. Effect of [Ser1]histogranin supplementation and ad- The present studies confirmed the antihyperalgesic
renal medullary or striated muscle transplants in the spinal sub-
effects of SHG, as intrathecal SHG attenuated CCI-arachnoid space on complete chronic constriction injury (CCI)-
induced thermal hyperalgesia and formalin flinching ininduced cold allodynia. Baseline latencies (BL, open bars) of
rats were evaluated prior to unilateral CCI, after CCI (cross- control transplanted animals as higher dose ranges were
hatched bars), and before (Pre-SHG; solid bars) and after reached. In adrenal medullary transplanted animals, in-(Post-SHG, diagonal bars) intrathecal treatment with saline ve- trathecal SHG was significantly more potent in reducinghicle or SHG (0.5, 1.0, or 3.0 µg). Mean percent withdrawals
both CCI-induced thermal hyperalgesia and formalin(of five trials) ± SEM in adrenal medullary (top panel, n = 14)
flinching, as effects were observed in the lower doseor striated muscle (bottom panel, n = 10) transplanted animals
are shown. ranges, and nearly complete pain suppression could be
achieved. In addition, attenuation of both CCI-induced
mechanical hyperalgesia and cold allodynia, not achieved
in the SHG dose ranges tested in the control transplantedSHG pretreatment did not significantly alter responses
to acetone in animals with control transplants except at group, was observed in animals with adrenal medullary
transplants. Thus, the combination of adrenal medullarythe 1.0 µg dose (p > 0.01 compared with CCI). The com-
bination of adrenal medullary grafts and SHG supple- transplants supplemented with SHG provided a more
complete suppression of the constellation of abnormalmentation was significantly more effective than combi-
nations with striated muscle grafts in reducing cold sensory symptoms in neuropathic and inflammatory pain.
The formalin model is a model for neurogenic in-allodynia [overall F(1, 22) = 8.88, p < 0.001].
Figure 5 shows an example of an adrenal medullary flammation that consists of two phases. The initial phase
is thought to reflect acute pain responses due to the di-graft in the spinal subarachnoid space. Chromaffin cells
were stained with tyrosine hydroxylase for identifica- rect activation of nociceptors, while the second phase is
ADRENAL TRANSPLANTS AND NMDA ANTAGONISTS REDUCE PAIN 209
Figure 5. Appearance of adrenal medullary transplants in the spinal subarachnoid space. Healthy
clusters of chromaffin cells are shown stained for tyrosine hydroxylase. Cells and clusters are
interspersed with connective and vascular tissue.
thought to reflect tonic pain, which may involve central trol transplanted animals in this dose range. Similarly,
cold allodynia was markedly, although incompletely,neuroplastic mechanisms developing during the quies-
cent interphase, modeling a progression to chronic pain. suppressed by the combination of SHG and adrenal med-
ullary transplants, while SHG in this dose range wasThe second phase is thought to be initiated in part by
activation of spinal NMDA receptors (4,8,43). Previous only marginally effective in control transplanted animals.
These findings suggest that neuropathic pain symptomsfindings in our laboratory have demonstrated that in-
trathecal injection of SHG suppresses the second, but amenable to adrenal medullary transplants can be further
enhanced by the addition of SHG, while symptoms onlynot the first, phase of the formalin test, and that adrenal
medullary transplants also more potently and consis- weakly affected by these transplants can be significantly
improved by this addition.tently suppress phase 2 in this model (33,34). Thus, it
is not surprising that the combination nearly suppressed It is interesting to note that pain responses were often
incompletely suppressed, even at the highest doses ofphase 2 flinching responses, while having only modest
effects on phase 1. These findings suggest that this ap- SHG employed, and that the highest doses were not sub-
stantially more potent than lower doses in animals withproach may be particularly useful in the treatment of the
nonacute stages of chronic inflammatory pain. adrenal medullary transplants. A U-shaped dose–response
effect of SHG has been noted in previous antinocicep-Both adrenal medullary transplants and NMDA an-
tagonists have also been shown to produce differing ef- tive studies, with intermediate doses being the most po-
tent, and suggested that SHG may act in a partial agonistfects on thermal and mechanical hyperalgesia and allo-
dynia, depending on the models and tests employed. In fashion at the NMDA receptor (34). Regardless of mecha-
nism, these findings indicate that maximum achievablethe present study, thermal hyperalgesia following pe-
ripheral nerve injury was nearly completely reversed by pain suppression effects of this combination have been
reached in this selected dose range, and that some as-the combination of low doses of intrathecal SHG and
adrenal medullary transplants, and reversed by higher pects of chronic neuropathic and inflammatory pain are
likely to be partially attenuated, but not completely sup-doses of SHG in control transplanted animals. In con-
trast, the addition of SHG suppressed mechanical hyper- pressed.
In summary, the results of this study demonstrate thatalgesia in adrenal medullary transplanted animals, while
producing only marginal nonsignificant effects in con- pain alleviation by adrenal medullary transplants can be
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